Earnings Call · Q2 FY2025·2025-08-08

Q2 25EPS +5.75%·Rev n/aQ1 25EPS -28.01%·Rev n/aQ4 24EPS -15.38%·Rev n/aQ3 24EPS +14.24%·Rev n/a⚠ consensus missing

NEKTAR THERAPEUTICS NKTR

Korin Franklin — Investor Relations

Howard W. Robin — President and Chief Executive Officer

Jonathan Zalevsky — Chief Research and Development Officer

Sandra A. Gardiner — Chief Financial Officer

−3.1%1d on move date−3.0% vs SPY3d+0.1%5d+14.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NKTR calls or request research access.

More NKTR calls Browse calls Request research access